Search Results - "STERN, Jerry O"

Baseline Hepatitis C Virus (HCV) NS3 Polymorphisms and Their Impact on Treatment Response in Clinical Studies of the HCV NS3 Protease Inhibitor Faldaprevir by BERGER, Kristi L, TRIKI, Ibtissem, KUKOLJ, George, CARTIER, Mireille, MARQUIS, Martin, MASSARIOL, Marie-Josée, BÖCHER, Wulf O, DATSENKO, Yakov, STEINMANN, Gerhard, SCHERER, Joseph, STERN, Jerry O

“…OA  Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment by Sarrazin, Christoph, Manns, Michael, Calleja, Jose Luis, Garcia-Samaniego, Javier, Forns, Xavier, Kaste, Renee, Bai, Xiaofei, Wu, Jing, Stern, Jerry O

“…This study evaluated the interferon-free, oral combination of deleobuvir (non-nucleoside HCV NS5-RNA-polymerase inhibitor) and faldaprevir (HCV NS3/4A-protease…”
Get full text

Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir by Berger, Kristi L, Sarrazin, Christoph, Nelson, David R, Scherer, Joseph, Sha, Nanshi, Marquis, Martin, Côté-Martin, Alexandra, Vinisko, Richard, Stern, Jerry O, Mensa, Federico J, Kukolj, George

“…The resistance profile of anti-hepatitis C virus (HCV) agents used in combination is important to guide optimal treatment regimens. We evaluated baseline and…”
Get full text

Drug-Induced Liver Injury Associated with the Use of Nonnucleoside Reverse-Transcriptase Inhibitors by Dieterich, Douglas T., Robinson, Patrick A., Love, James, Stern, Jerry O.

“…Human immunodeficiency virus (HIV)-infected patients frequently present with elevated levels of serum transaminases (alanine aminotransferase [ALT] and/or…”
Get full text

Antiviral Effect, Safety, and Pharmacokinetics of Five-Day Oral Administration of Deleobuvir (BI 207127), an Investigational Hepatitis C Virus RNA Polymerase Inhibitor, in Patients with Chronic Hepatitis C by LARREY, Dominique, LOHSE, Ansgar W, BERGER, Kristi L, MARQUIS, Martin, STEFFGEN, Jürgen, KUKOLJ, George, TREPO, Christian, BRONOWICKI, Jean-Pierre, ARASTEH, Keikawus, BOURLIERE, Marc, CALLEJA, Jose Luis, STERN, Jerry O, NEHMIZ, Gerhard, ABDALLAH, Nasri

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection by Asselah, Tarik, Zeuzem, Stefan, Soriano, Vicente, Bronowicki, Jean-Pierre, Lohse, Ansgar W, Müllhaupt, Beat, Schuchmann, Marcus, Bourlière, Marc, Buti, Maria, Roberts, Stuart K, Gane, Edward J, Stern, Jerry O, Voss, Florian, Baum, Patrick, Gallivan, John-Paul, Böcher, Wulf O, Mensa, Federico J

“…Whether inosine triphosphatase (ITPA) gene polymorphisms predict anemia during interferon-free therapy in chronic hepatitis C virus (HCV)-infected patients is…”
Get full text

Safety and efficacy of faldaprevir in combination with pegylated interferon α‐2b and ribavirin in Japanese patients with genotype‐1 chronic hepatitis C virus infection by Nishiguchi, Shuhei, Urano, Yasuhisa, Suzaki, Keiko, Taniguchi, Atsushi, Scherer, Joseph, Berger, Kristi L., Quinson, Anne‐Marie, Stern, Jerry O., Omata, Masao

“…Aim We evaluated the safety and efficacy of the hepatitis C virus (HCV) NS3/4A A protease inhibitor faldaprevir plus pegylated interferon α‐2b and ribavirin…”
Get full text

Faldaprevir and Deleobuvir for HCV Genotype 1 Infection by Zeuzem, Stefan, Soriano, Vincent, Asselah, Tarik, Bronowicki, Jean-Pierre, Lohse, Ansgar W, Müllhaupt, Beat, Schuchmann, Marcus, Bourlière, Marc, Buti, Maria, Roberts, Stuart K, Gane, Ed J, Stern, Jerry O, Vinisko, Richard, Kukolj, George, Gallivan, John-Paul, Böcher, Wulf-Otto, Mensa, Federico J

“…In this phase 2b study, an interferon-free regimen consisting of the combination of a protease inhibitor (faldaprevir), a nonnucleoside polymerase inhibitor…”
Get full text

Faldaprevir combined with pegylated interferon alfa‐2a and ribavirin in treatment‐naïve patients with chronic genotype1 HCV: SILEN‐C1 trial by Sulkowski, Mark S., Asselah, Tarik, Lalezari, Jacob, Ferenci, Peter, Fainboim, Hugo, Leggett, Barbara, Bessone, Fernando, Mauss, Stefan, Heo, Jeong, Datsenko, Yakov, Stern, Jerry O., Kukolj, George, Scherer, Joseph, Nehmiz, Gerhard, Steinmann, Gerhard G., Böcher, Wulf O.

“…Faldaprevir (BI 201335) is a potent, hepatitis C virus (HCV) NS3/4A protease inhibitor with pharmacokinetic properties supportive of once‐daily (QD) dosing…”
Get full text

Hepatic profile analyses of tipranavir in Phase II and III clinical trials by Mikl, Jaromir, Sulkowski, Mark S, Benhamou, Yves, Dieterich, Douglas, Pol, Stanislas, Rockstroh, Jürgen, Robinson, Patrick A, Ranga, Mithun, Stern, Jerry O

“…The risk and course of serum transaminase elevations (TEs) and clinical hepatic serious adverse event (SAE) development in ritonavir-boosted tipranavir (TPV/r)…”
Get full text

Efficacy of the Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127, and Ribavirin in Patients With Chronic HCV Infection by Zeuzem, Stefan, Asselah, Tarik, Angus, Peter, Zarski, Jean–Pierre, Larrey, Dominique, Müllhaupt, Beat, Gane, Ed, Schuchmann, Marcus, Lohse, Ansgar, Pol, Stanislas, Bronowicki, Jean–Pierre, Roberts, Stuart, Arasteh, Keikawus, Zoulim, Fabien, Heim, Markus, Stern, Jerry O, Kukolj, George, Nehmiz, Gerhard, Haefner, Carla, Boecher, Wulf Otto

“…Background & Aims Therapeutic regimens are being developed for patients with hepatitis C virus (HCV) infection that do not include the combination of…”
Get full text

Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection by Manns, Michael P, Bourlière, Marc, Benhamou, Yves, Pol, Stanislas, Bonacini, Maurizio, Trepo, Christian, Wright, David, Berg, Thomas, Calleja, José L, White, Peter W, Stern, Jerry O, Steinmann, Gerhard, Yong, Chan-Loi, Kukolj, George, Scherer, Joe, Boecher, Wulf O

“…Background & Aims BI201335 is a highly specific and potent HCV protease inhibitor. This multiple rising dose trial evaluated antiviral activity and safety in…”
Get full text

Faldaprevir combined with peginterferon alfa‐2a and ribavirin in chronic hepatitis C virus genotype‐1 patients with prior nonresponse: SILEN‐C2 trial by Sulkowski, Mark S., Bourlière, Marc, Bronowicki, Jean‐Pierre, Asselah, Tarik, Pawlotsky, Jean‐Michel, Shafran, Stephen D., Pol, Stanislas, Mauss, Stefan, Larrey, Dominique, Datsenko, Yakov, Stern, Jerry O., Kukolj, George, Scherer, Joseph, Nehmiz, Gerhard, Steinmann, Gerhard G., Böcher, Wulf O.

“…Faldaprevir (BI 201335) is a potent, hepatitis C virus (HCV) NS3/4A protease inhibitor. In all, 290 noncirrhotic HCV genotype (GT)‐1 patients with prior null…”
Get full text

Mechanisms underlying benign and reversible unconjugated hyperbilirubinemia observed with faldaprevir administration in hepatitis C virus patients by Sane, Rucha S, Steinmann, Gerhard G, Huang, Qihong, Li, Yongmei, Podila, Lalitha, Mease, Kirsten, Olson, Stephen, Taub, Mitchell E, Stern, Jerry O, Nehmiz, Gerhard, Böcher, Wulf O, Asselah, Tarik, Tweedie, Donald

“…Faldaprevir, an investigational agent for hepatitis C virus treatment, is well tolerated but associated with rapidly reversible, dose-dependent, clinically…”
Get more information

Faldaprevir and Deleobuvir for HCV Genotype 1 Infection by ZEUZEM, Stefan, SORIANO, Vincent, GANE, Ed J, STERN, Jerry O, VINISKO, Richard, KUKOLJ, George, GALLIVAN, John-Paul, BÖCHER, Wulf-Otto, MENSA, Federico J, ASSELAH, Tarik, BRONOWICKI, Jean-Pierre, LOHSE, Ansgar W, MÜLLHAUPT, Beat, SCHUCHMANN, Marcus, BOURLIERE, Marc, BUTI, Maria, ROBERTS, Stuart K

Get full text

SILEN-C3, a Phase 2 Randomized Trial with Faldaprevir plus Pegylated Interferon α-2a and Ribavirin in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients by DIETERICH, Douglas, ASSELAH, Tarik, STERN, Jerry O, OZAN, Melek, DATSENKO, Yakov, BÖCHER, Wulf Otto, STEINMANN, Gerhard, GUYADER, Dominique, BERG, Thomas, SCHUCHMANN, Marcus, MAUSS, Stefan, RATZIU, Vlad, FERENCI, Peter, LARREY, Dominique, MAIERON, Andreas

“…Faldaprevir is an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor which, when administered for 24 weeks in combination with pegylated…”
Get full text

STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection by Ferenci, Peter, Asselah, Tarik, Foster, Graham R, Zeuzem, Stefan, Sarrazin, Christoph, Moreno, Christophe, Ouzan, Denis, Maevskaya, Marina, Calinas, Filipe, Morano, Luis E, Crespo, Javier, Dufour, Jean-François, Bourlière, Marc, Agarwal, Kosh, Forton, Daniel, Schuchmann, Marcus, Zehnter, Elmar, Nishiguchi, Shuhei, Omata, Masao, Kukolj, George, Datsenko, Yakov, Garcia, Miguel, Scherer, Joseph, Quinson, Anne-Marie, Stern, Jerry O

“…Background & Aims The efficacy and tolerability of faldaprevir, a potent hepatitis C virus (HCV) NS3/4A protease inhibitor, plus peginterferon (PegIFN) and…”
Get full text

Su1025 Interferon-Stimulated Gene Expression Is Associated With Treatment Response to Faldaprevir Plus Pegylated Interferon α-2A and Ribavirin in Patients With Chronic HCV Genotype-1 Infection by Datsenko, Yakov, Baum, Patrick, Schirmbeck, Reinhold, Stern, Jerry O, Sha, Nanshi, Steinmann, Gerhard G

Get full text

Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin by Larrey, Dominique, Lohse, Ansgar W, de Ledinghen, Victor, Trepo, Christian, Gerlach, Tilman, Zarski, Jean-Pierre, Tran, Albert, Mathurin, Philippe, Thimme, Robert, Arastéh, Keikawus, Trautwein, Christian, Cerny, Andreas, Dikopoulos, Nektarios, Schuchmann, Marcus, Heim, Markus H, Gerken, Guido, Stern, Jerry O, Wu, Katherine, Abdallah, Nasri, Girlich, Birgit, Scherer, Joseph, Berger, Frank, Marquis, Martin, Kukolj, George, Böcher, Wulf, Steffgen, Jürgen

“…Background & Aims BI 207127 is a potent non-nucleoside hepatitis C virus (HCV) NS5B polymerase inhibitor in vitro. Methods In this double-blind,…”
Get full text

A Comprehensive Hepatic Safety Analysis of Nevirapine in Different Populations of HIV Infected Patients by Stern, Jerry O, Robinson, Patrick A, Love, James, Lanes, Stephan, Imperiale, Michael S, Mayers, Douglas L

“…All classes of anti-retroviral (ARV) therapy have been associated with asymptomatic elevations of alanine aminotransferase/aspartate aminotransferase (ALT/AST)…”
Get full text